ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ocular Therapeutix and Ollin Biosciences side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Ocular TherapeutixOllin Biosciences
studies on the registry335
open to participants now24
phase 3 studies under way44
reach primary completion within a year20
programswith a study of their own in two years21

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOcular TherapeutixOllin Biosciences
Phase 100%00%
Phase 200%00%
Phase 3100%

Ollin Biosciences: 1 of its 1 programs at phase 3

  1. OLN324phase 3
100%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ocular Therapeutix2 readouts · 2 phase 3··

Ocular Therapeutix, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Axitinibphase 3 · Jan 8 · NCT06495918
·

Ocular Therapeutix, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24phase 3 · Mar 0 · NCT07235085
·······
Ollin Biosciences0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ocular Therapeutix

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Ollin Biosciences

New programs 0

None

Reached a new phase 1

  • OLN324phase 3 · Sep 7 · Macular Degeneration

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionOcular TherapeutixOllin Biosciences
Diabetic Retinopathyboth · compare here

Ollin Biosciences in Diabetic Retinopathy: 1 program

  1. OLN324phase 3

Their studies: Ollin Biosciences’ studies of Diabetic Retinopathy in search

Macular Degenerationboth · compare here

Ocular Therapeutix in Macular Degeneration: 1 program

  1. Axitinibphase 3

Their studies: Ocular Therapeutix’s studies of Macular Degeneration in search

Ollin Biosciences in Macular Degeneration: 1 program

  1. OLN324phase 3

Their studies: Ollin Biosciences’ studies of Macular Degeneration in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Ocular Therapeutix 1 of 2 · Ollin Biosciences 0 of 1 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.